Core Points - The original controlling shareholder of Qidi Pharmaceutical, Qidi Kefu, sold 58,606,962 shares, representing 24.47% of the total share capital, to Hunan Sailoxian through a successful auction on July 15, 2025 [1] - The transfer of related property rights occurred on August 6, 2025, followed by the completion of stock transfer registration [1] - A temporary shareholders' meeting was held to elect Jiang Xin as the chairman and CEO of the company [1] - Following the adjustment in shareholding structure and governance, the controlling shareholder has changed to Hunan Sailoxian, with Jiang Xin as the actual controller [1] - Currently, among the shareholders holding more than 5%, Hunan Sailoxian holds 24.47% and Hengyang Hongxiang State-owned Investment (Holding) Group Co., Ltd. holds 19.11% [1] - As of the announcement date, the change in control has been completed, and the company's operations remain stable without significant impact [1]
启迪药业控制权变更完成,湖南赛乐仙成控股股东